2型糖尿病患者血清25-羟维生素D水平的调查与分析

目的调查2型糖尿病(T2DM)患者血清25-羟维生素D[25(OH)D]水平,并分析25(OH)D和糖尿病之间的相关性。方法选择2016年10月-2018年9月期间该院收治的80例T2DM患者并作为试验组,另选择同期体检健康的志愿者100名作为对照组,检测两组入选对象血清25(OH)D水平及相关临床及生化指标。结果试验组病例25(OH)D低于对照组,FBG、SDP、SBP、BUN、TG水平高于对照组,差异有统计学意义(P<0.05);将试验组病例分为不同年龄组,发现男、女性年龄≥70岁年龄组25(OH)D水平最高,分别为(39.69±17.33)mmol/L、(38.04±16.55)mmol/L,相同年龄段中男女25(OH)D水平差异有统计学意义(P<0.05);且相关性分析表明,25(OH)D水平和空腹血糖之间存在负相关性(P<0.05)。结论T2DM患者血清25(OH)D水平低于正常者,通常情况下年龄越大25(OH)D水平越高;空腹血糖水平越高,25(OH)D水平越低。     

老年骨折患者血清25-羟基维生素D和甲状旁腺激素水平与骨质疏松程度的关系

目的探讨老年骨折患者血清25-羟基维生素D(25OHD)和甲状旁腺激素(PTH)水平与骨质疏松程度的关系。方法选择128例老年骨折患者为研究组,选择同时期健康体检的46名老年人作为对照组,采用双能X线骨密度仪测定腰椎L2、L3、L4及左侧股骨大粗隆部位的骨质密度,根据骨密度将患者分为骨质疏松组、骨量减少组和骨量正常组3个亚组,酶联免疫分析法测定血清25OHD和PTH水平,分析25OHD和PTH水平与骨质密度的相关性。结果研究组骨质疏松的发病率明显高于对照组,骨密度小于对照组(均P0.01);骨量正常组的25OHD和PTH水平高于骨量减少组和骨质疏松组(P0.05);25OHD和PTH水平与骨质疏松程度呈正相关(r=0.412、0.357,均P0.05)。结论老年骨折患者骨质疏松发病率较高,血清25OHD和PTH水平与骨质疏松程度呈正相关,25OHD和PTH水平可作为诊断骨质疏松的有效指标。     

老年高血压病患者颈动脉粥样硬化程度与血25-羟维生素D水平的相关性

目的　探讨老年高血压病患者颈动脉粥样硬化程度与血25-羟维生素D［25（OH）D］水平的相关性。方法　对2012年5月至12月间在宁波市第二医院就诊的老年高血压病患者经超声检测颈动脉内膜中膜厚度（IMT）,根据颈动脉IMT将患者分为颈动脉正常组（60例,对照组）、颈动脉内膜增厚组（60例）和颈动脉斑块组（60例）。采用ELISA法测定三组患者血清25（OH）D水平,分析25（OH）D水平与颈动脉IMT的关系。结果　颈动脉斑块组与颈动脉内膜增厚组血25（OH）D水平均低于颈动脉正常组（P<0.05）,颈动脉斑块组血25（OH）D水平低于颈动脉内膜增厚组（P<0.05）,差异均有统计学意义。结论　低血25（OH）D水平的老年高血压病患者具有颈动脉粥样硬化程度加重的危险,血25（OH）D水平测定有助于预测颈动脉粥样硬化程度。     

重庆老年患者血清25-羟维生素D水平调查

目的调查重庆西南医院老年科住院患者血清25-羟维生素D状况。方法对住院老年患者行问卷调查,测定空腹血清25-羟维生素D含量,采用SPSS13.0软件对所得数据进行统计学处理。结果共调查342例住院患者,血清25-羟维生素D测定值为(14.62±7.96)ng/mL,血清25-羟维生素D水平与性别和年龄无相关性,维生素D缺乏和不足者占住院老年患者的93.27%,维生素D充足者6.72%。补充钙剂组患者血清25-羟维生素D水平均高于未补钙组,差异有统计学意义。补充活性维生素D组患者与未补充活性维生素D组血清25-羟维生素D水平差异无统计学意义。结论重庆市老年住院患者普遍缺乏维生素D,常规监测血清25-羟维生素D含量和积极预防和治疗维生素D缺乏十分必要。     

2型糖尿病患者血清25羟维生素D3水平与周围神经病变的相关性

目的探讨2型糖尿病(T2DM)患者血清25羟维生素D3〔25-(OH)D3〕水平与周围神经病变(DPN)的相关性。方法选择2015年1~10月在该院就诊的T2DM患者124例,其中64例合并DPN的患者为观察组,另60例单纯T2DM患者为对照组,比较两组实验室指标水平及血清25-(OH)D3相关指标情况,分析血清25-(OH)D3与DPN的相关性。结果两组血肌酐、甲状旁腺激素(PTH)、血钙、血磷水平比较无显著差异(P0.05)。观察组的血清25-(OH)D3水平显著低于对照组,25-(OH)D3含量20 ng/ml的比例显著高于对照组(P0.05)。Pearson相关分析发现,血清25-(OH)D3与DPN的发病呈负相关。结论 T2DM合并DPN的患者血清25-(OH)D3水平显著低于单纯T2DM患者,且血清25-(OH)D3与DNP之间呈负相关联系。     

25羟维生素D及甲状旁腺激素与高血压的关系

目的目前血清25羟维生素D[25-(OH)D]、甲状旁腺激素(PTH)与高血压是否直接相关尚无定论,文章旨在探讨三者之间的关系。方法选取2014年3月至2015年7月就诊于盛京医院心血管内科的患者368例,其中男性202例。按照是否患高血压分为高血压组(198例)和非高血压组(170例)。收集研究对象一般资料并检测PTH以及25-(OH)D水平。分析25-(OH)D、PTH与高血压之间的关系。结果高血压组患者25-(OH)D水平低于非高血压组(37.67±18.23 nmol/L比42.45±20.41 nmol/L,P=0.018)。两组间PTH水平差异无统计学意义(50.08±28.80 ng/L比50.45±22.37 ng/L,P=0.892)。Pearson相关性分析显示,25-(OH)D与PTH呈负相关(r=-0.225,P0.05)。二元Logistic回归分析显示维生素D缺乏或不足是高血压的独立危险因素(OR=1.847,95%CI 1.138~2.996,P=0.013),PTH升高与高血压发病风险不存在相关。结论维生素D不足或缺乏与高血压相关,是高血压的危险因素。     

2型糖尿病患者血清25-羟维生素D水平及其与骨密度的关系

目的 了解2型糖尿病患者血清25-羟维生素D（25-hydroxylvitamin D,25OHD）营养状况及其与骨密度（bone mineral density,BMD）的关系。方法 选择2015年2月-2017年3月在北京同仁医院住院的2型糖尿病患者716例（男性410例,女性306例）,年龄32~93岁,平均年龄（58.78±11.31）岁,检测血清25OHD水平,应用双能X线吸收检测法测定腰1-4、全髋及股骨颈的BMD。结果 在716例2型糖尿病患者中,维生素D严重缺乏者为230例（32.1%）,缺乏357例（49.9%）,不足97例（13.5%）,充足仅32例（4.5%）。不同年龄组别中,血清25OHD水平以及缺乏程度差异均无统计学意义（P > 0.05）。Logistic回归分析显示年龄增长、女性及维生素D缺乏为2型糖尿病患者发生骨质疏松的危险因素。结论 2型糖尿病患者维生素D缺乏严重,女性更为明显。血清25OHD缺乏程度越重,骨质疏松的发生风险越高。     

糖尿病肾病患者血清25-羟维生素D3变化及意义

目的 探讨糖尿病肾病(DN)患者血清25-羟维生素D3[25-(OH) D3]变化的临床意义.方法 选择2型糖尿病患者90例,根据尿白蛋白排泄率水平,将其分为非DN组、早期DN组、临床DN组各30例.采用电化学发光法检测三组血清25-(OH)D3,以及空腹血糖(FPG)、血脂、血钙、血磷、血肌酐、CRP、补体C3及C4,并分析DN患者血清25-(OH)D3水平与各检测指标的相关性.结果 非DN组、早期DN组、临床DN组的血清25-(OH) D3逐渐降低,FPG、补体C3、CRP逐渐升高,组间比较均有统计学差异(P均＜0.05);临床DN组血钙低于非DN组、早期DN组(P均＜0.05).血清25-(OH)D3水平与CRP、C3、FPG及血肌酐均呈负相关(P均＜0.05).结论 维生素D3缺乏与DN的发生、发展密切相关.     

2型糖尿病患者血清25羟维生素D水平与蛋白尿的关系

目的 分析2型糖尿病(T2DM)患者血清25羟维生素D[25(OH)D]水平与蛋白尿的关系.方法 T2DM患者344例,根据尿微量白蛋白/肌酐比值(UACR)分为单纯糖尿病组(145例)、微量蛋白尿组(30 mg/g≤UACR<300 mg/g)和大量蛋白尿组(UACR≥300 mg/g),比较三组间25(OH)D水平...     

血清25-羟维生素D3与2型糖尿病相关性分析

目的 探讨血清25-羟维生素D3 [25-（OH） D3]与2型糖尿病的关系.方法 选择2型糖尿病患者41例,同期健康体检者32例,比较两组间血糖、血脂、糖化血红蛋白（HbA1C）、空腹C-肽（FC-P）、血清25-（OH） D3等指标的差异,并对25-（OH）D3与上述指标进行相关性分析.结果 与对照组比较,2型糖尿病组患者空腹血糖（FPG）、餐后2小时血糖（2hPG）、HbA1C、总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）、HOMA模型胰岛素抵抗指数（HOMA-IR）均明显升高,血清25-（OH） D3水平、HOMA模型β细胞功能指数（HOMA-IS）明显降低,差异有统计学意义（P＜0.05）.两组FC-P、空腹胰岛素（FINS）、高密度脂蛋白胆固醇（HDL-C）比较,差异无统计学意义（P＞0.05）.血清25-（OH） D3与HbA1C呈负相关（r=-0.386,P＜0.05）,与TG呈负相关（r=-0.391,P＜0.05）,与HOMA-IS呈正相关（r=0.434,P＜0.05）.结论 血清25-（OH）D3可能通过直接或间接作用影响胰岛β细胞功能,并影响血脂代谢.     

Association of betatrophin amounts with 25-(OH)D levels in patients with gestational diabetes mellitus

To determine the association of betatrophin amounts with 25-(OH)D levels in gestational diabetes mellitus (GDM) patients, and to provide new targets for the prevention and treatment of GDM.This study included 40 GDM patients (GDM group) and 37 healthy pregnant women (control group). Betatrophin, 25-(OH)D, fasting blood glucose (FBG), HbA1c, hsCRP, and FINS levels in peripheral blood, as well as betatrophin and 25-(OH)D amounts in cord blood, were measured. Then, associations of betatrophin levels with 25-(OH)D amounts and other indexes were determined.Maternal (P = .011) and cord (P = .022) blood betatrophin levels were significantly lower in the GDM group compared with control group. Cord blood betatrophin levels were higher compared with maternal blood amounts in both the GDM and control groups (both P = .000). Serum betatrophin levels were positively associated with 25-(OH)D levels (r = 0.677, P = .000), but negatively associated with hsCRP (r = −0.335, P = .037) and HOMA-IR (r = −0.346, P = .031) levels in the GDM group. Fetal weight was higher in the GDM group compared with control group (P = .023), and negatively associated with cord blood betatrophin amounts in the GDM group (r = −0.342, P = .031). However, cord blood betatrophin levels were not significantly associated with body length, Apgar score, and cord blood 25-(OH)D levels in the GDM group (all P > .05).Serum betatrophin and 25-(OH) D levels were positively associated in women with GDM, and both significantly lower compared with control values. Fetal weight was higher in the GDM group and associated with cord blood betatrophin. These findings provide insights into developing new predictive biomarkers or therapeutic targets for GDM.     

Association between serum 25 (OH) D levels and depression symptoms in adults with prediabetes

Background and aimDepression symptoms are a significant risk factor for prediabetes-related diabetes, and low vitamin D levels are connected with depression symptoms. The goal of this study is to examine the association between vitamin D and depression symptoms in prediabetic persons.MethodsThis cross-sectional survey was conducted in Tianjin, China, among 4051 individuals. Symptoms of depression were assessed using the Self-Rating Depression Scale (SDS) (cut-off point SDS ≥45). Serum 25 (OH) D concentrations were determined using an enzyme immunoassay (OCTEIA 25-hydroxy Vitamin D, IDS Ltd, UK) and classified into three levels: 50 nmol/L, 50–75 nmol/L, and >75 nmol/L. The link between serum 25 (OH) D concentrations and depression symptoms in prediabetes was investigated using multiple logistic regression analysis. The models were adjusted for a variety of potential confounders.ResultsThe prevalence of symptoms of depression in prediabetic adults was 14.2% (12.5% males and 16.4% females). After adjusting for potentially confounding variables, the odds ratios - ORs for symptoms of depression in women across serum 25 (OH) D levels were 1.00 (reference), 1.03 (0.57, 1.39), and 0.28 (0.12, 0.57), respectively (p = 0.0015). However, no statistically significant connection was discovered in males.ConclusionIn women with prediabetes, we showed a substantial negative connection between serum 25 (OH) D levels and depressed symptoms. Vitamin D supplementation may be an effective way to decrease the risk of depression symptoms in women with prediabetes.     

The relationship between balance and vitamin 25(OH)D in fibromyalgia patients

Introduction: Fibromyalgia syndrome (FMS) is a chronic disease characterized by diffuse pain of unknown cause, fatigue, sleep disorders, cognitive dysfunction, and sensitivity. Fibromyalgia was shown to be associated with balance problems and increased incidence of falls. There are many theoretical mechanisms related to the impact of vitamin D on postural control. The aim of the current study was to investigate the relationship between vitamin 25(OH)D levels and pain, balance and daily activities in patients with FMS.

Method: Patients aged 35–65 years who were diagnosed with FMS according to 1990 ACR diagnostic criteria were screened. Seventy patients diagnosed with FMS and 60 healthy controls with comparable age and gender were included in the study. Fibromyalgia impact scale (FIQ), Berg Balance Scale (BBS), the Nottingham Health Profile (NHP), and visual analog scale (VAS) were applied to the subjects. The subjects were divided into two groups by vitamin 25(OH)D level being above or below 30?ng/ml.

Results: A statistically significant difference was established between VAS, BBS value and all NHP subscale and NHP total values of FMS patients and those of healthy control group. The relationship between BBS and the level of vitamin 25(OH)D of all participants was investigated, a positive statistically significant relationship was found with Vit-D at r?=?0.481 level (p?Conclusion:: It was observed that low vitamin D levels affected balance in both FMS group and healthy control group. It should be kept in mind that vitamin D level is likely to negatively affect balance and VAS values in FMS.     

血清25(OH)D_3水平在哮喘发作期、治疗后的变化及与肺功能的相关性分析

目的探讨哮喘患者急性期及治疗后血清25(OH)D_3水平与肺功能及病情的相关性。方法选取来我院诊治的急性发作期哮喘患者60例为研究组,分为成年亚组及未成年亚组各30例,于治疗前及治疗后7d(缓解期),治疗后3个月测定其血清25(OH)D_3水平、第1秒用力呼气容积占预计值百分比(FEV1%pred)、呼气峰流速(PEF),于治疗前及治疗3个月后进行哮喘控制评分(ACT);于上述时间点选择健康人群为对照组测量相应指标,比较健康与患病人群两亚组间各项指标差异,并分析治疗前及3个月后研究组两亚组血清25-(OH)D_3水平与其他指标间的相关性。结果治疗前发作期、开始治疗后7d及3个月,对照组与研究组各亚组之间,各指标均有显著差异;而研究组治疗7d后血清25(OH)D_3水平也远高于治疗前。治疗前两亚组血清25(OH)D_3与FEV1%pred、PEF间无明显相关性;而开始治疗3个月后,两亚组血清25(OH)D_3与FEV1%pred、PEF及ACT评分均有显著正相关(未成年r=0.81,0.79,0.82;P均0.05;成年组r=0.61,0.54,0.70;P均0.05)。结论哮喘患者发作、缓解及稳定期血清25(OH)D_3水平在病情的诊断与预后评估中能发挥重要作用,值得进一步大样本深入研究。     

维生素D与2型糖尿病合并肺部感染相关性

目的观察2型糖尿病合并肺部感染患者维生素D缺乏程度,研究维生素D与2型糖尿病合并肺部感染的相关性。方法收集360例2型糖尿病合并肺部感染患者作为研究对象,根据是否存在肺部感染分为观察组与对照组,其中观察组151例,对照组209例,两组患者均进行维生素D水平及相关的炎症指标ESR、CRP、PCT等检测,从而探讨维生素D与2型糖尿病合并肺部感染的相关性。结果 1观察组中发现维生素D不足可高达79.47%,而在对照组高达66.51%(P0.01);维生素水平减少在观察组中高达58.94%,在对照组中高达40.19%(P0.01);三种不同程度的维生素D缺乏对2型糖尿病合并肺部感染的危险性分别为1.745倍、2.136倍、1.949倍。2观察组相关炎症因子PCT、ESR和CRP较对照组明显升高,差异有统计学意义(P0.01);观察组HbA1c较对照组明显偏高,差异有统计学意义(P0.01)。结论维生素D的缺乏在2型糖尿病患者中患病率较高,而在合并肺部感染中更高,维生素D缺乏可能是2糖尿病合并肺部感染的相关危险因素,维生素D的缺乏将不利于炎症的控制及血糖水平的控制。     

慢性肾脏病229例25羟基维生素D浓度及影响因素分析

目的了解慢性肾脏病(CKD)患者维生素D不足与缺乏情况及其相关因素。方法测定2009年1月至2010年9月北京大学人民医院229例非肾病综合征、非血液净化的CKD 1～5期患者血清25羟基维生素D[25(OH)D]及其他临床指标,分析维生素D不足及缺乏的发生率,应用Logistic回归分析维生素D缺乏的独立预测因子。结果 229例CKD患者25(OH)D浓度(30.23±13.95)nmol/L。维生素D浓度随CKD分期进展而呈现逐渐下降趋势。维生素D缺乏者169例(73.80%)。CKD各期间维生素D缺乏发生率差异有统计学意义,且随CKD分期的进展,维生素D缺乏的发生率有升高的趋势(χ2=18.289,P=0.001)。在除外糖尿病患者并对年龄进行校正后,维生素D缺乏的发生率在CKD各期间的差异仍具有统计学意义(P=0.025)。Logistic回归分析显示,血清白蛋白、磷及糖尿病是CKD患者25(OH)D缺乏的独立预测因子。结论非肾病综合征、非血液净化CKD患者维生素D不足及缺乏发生率高,且在CKD早期就已存在。血清白蛋白、磷及糖尿病是CKD非血液净化、非肾病综合征患者25(OH)D缺乏的独立预测因子。     

血清25羟维生素D3与2型糖尿病周围神经病变的相关性

目的：探讨血清25OH维生素D3（25OHD3）水平与2型糖尿病周围神经病变的关系。方法收集114例2型糖尿病患者,根据临床症状、体征和电生理检查,将患者分为糖尿病合并周围神经病变组（63例）和非糖尿病周围神经病变组（51例）,抽取所有受试者空腹静脉血检测血清25OHD3水平,比较2组患者血清25OHD3水平,分析25OHD3与2型糖尿病临床指标间的相关性。结果糖尿病周围神经病变组较非糖尿病周围神经病变组患者维生素D3缺乏发生率分别是79.4％和41.2％,差异有统计学意义（P＜0.01）;糖尿病周围神经病变组患者25OHD3水平低于非糖尿病周围神经病变组,分别为（40.1±12.7）nmol/L与（54.4±18.4）nmol/L,差异有统计学意义（P＜0.01）;25OHD3水平与2型糖尿病患者糖化血红蛋白（HbA1c）及糖尿病病程负相关（P值分别为0.01和0.044）。结论低25OHD3水平是2型糖尿病周围神经病变的危险因素,25OHD3水平与2型糖尿病患者病程和HbA1c相关。     

The relationship between serum 25(OH)D and parathyroid hormone levels

Objective

Low 25(OH)D levels are associated with increased parathyroid hormone levels leading to progressive bone loss. The serum levels of 25(OH)D sufficient to keep the parathyroid hormone level at a range that will prevent bone loss are still unclear. The current study was aimed at evaluating the relationship between 25(OH)D levels and concomitant parathyroid hormone levels.

Methods

The computerized laboratory database of Clalit Health Services, a not-for-profit health maintenance organization covering more than half of the Israeli population, was searched for all 25(OH)D and parathyroid hormone tests performed in 2009. Concomitant tests of parathyroid hormone and 25(OH)D were identified in 19,172 people.

Results

Serum parathyroid hormone levels were inversely correlated with 25(OH)D levels (r = −0.176, P < .001); 25(OH)D levels less than 50 nmol/L were associated with a steep increase in parathyroid hormone levels and hyperparathyroidism, which decreased with increasing 25(OH)D levels and reached a plateau at 25(OH)D levels of 75 to 85 nmol/L. The quadratic fit with plateau model showed that parathyroid hormone stabilizes at 25(OH)D level of 78.9 nmol/L. However, after excluding 5449 people with hypercalcemia or renal failure, the parathyroid hormone plateau was attained at a significantly lower 25(OH)D cut point of 46.2 nmol/L.

Conclusion

Our data suggest that a 25(OH)D threshold of 50 nmol/L is sufficient for parathyroid hormone suppression and prevention of secondary hyperparathyroidism in persons with normal renal function. 25(OH)D levels greater than 75 nmol/L do not seem to be associated with additional change in parathyroid hormone levels.     

毛细支气管炎患儿血清25-（OH）-D3水平、尿LTE4水平变化的临床意义及维生素D3干预对尿LTE4的影响0976

目的：探讨毛细支气管炎患儿血清25-( OH)-D3水平、尿LTE4水平变化的临床意义及维生素D3干预对尿LTE4的影响。方法选择毛细支气管炎急性期患儿76例作为毛细支气管炎组,另选取同期在我院儿童保健门诊体检的60例健康儿童作为对照组。毛细支气管炎组患儿给予常规治疗,进入恢复期后,随机分为维生素D3干预组和未干预组,每组各38例,干预组予维生素D3滴剂400IU/天口服,未干预组不予处理,随访6个月。分别于入院次日(急性期)、维生素D3干预前一日(恢复期)检测各组患儿血清25-( OH)-D3和尿LTE4水平,并干预6个月后检测干预组及未干预组尿LTE4水平。结果毛细支气管炎重型及轻型患儿血清25-( OH)-D3水平均明显低于对照组;而尿LTE4则明显高于对照组;重型患儿血清25-( OH)-D3水平明显低于轻型患儿,尿LTE4水平明显高于轻型(P<0．05);急性期及恢复期血清25-(OH)-D3水平均低于对照组,尿LTE4水平明显高于对照组;急性期25-( OH)-D3水平明显低于恢复期;尿LTE4水平则明显高于恢复期(P均<0．01)。血清25-(OH)-D3与毛细支气管炎病情轻重呈负相关(r=-0．68,P<0．01),尿LTE4与病情轻重呈正相关(r=0．76,P<0．01);血清25-(OH)-D3与尿LTE4呈负相关(r=-0．63,P<0．05)。干预后,干预组及未干预组尿LTE4水平比较,两组之间差异无统计学意义( P>0．05)。结论毛细支气管炎患儿急性期维生素D3干预对尿LTE4无下调作用。